Chemotherapy response and recurrence-free survival in Neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Laura J. Esserman, Donald A. Berry, Maggie C U Cheang, Christina Yau, Charles M. Perou, Lisa Carey, Angela De Michele, Joe W. Gray, Kathleen Conway-Dorsey, Marc E. Lenburg, Meredith B. Buxton, Sarah E. Davis, Laura J. Van't Veer, Clifford Hudis, Koei Chin, Denise Wolf, Helen Krontiras, Leslie Montgomery, Debu Tripathy, Constance LehmanMinetta C Liu, Olufunmilayo I. Olopade, Hope S. Rugo, John T. Carpenter, Chad Livasy, Lynn Dressler, David Chhieng, Baljit Singh, Carolyn Mies, Joseph Rabban, Yunni Yi Chen, Dilip Giri, Alfred Au, Nola Hylton

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging and molecular signatures, with outcomes of pathologic complete response (pCR) and RFS. The current analysis was performed using data from patients who had molecular profiles and did not receive trastuzumab. The various molecular classifiers tested were highly correlated. Categorization of breast cancer by molecular signatures enhanced the ability of pCR to predict improvement in RFS compared to the population as a whole. In multivariate analysis, the molecular signatures that added to the ability of HR and HER2 receptors, clinical stage, and pCR in predicting RFS included 70-gene signature, wound healing signature, p53 mutation signature, and PAM50 risk of recurrence. The low risk signatures were associated with significantly better prognosis, and also identified additional patients with a good prognosis within the no pCR group, primarily in the hormone receptor positive, HER-2 negative subgroup. The I-SPY 1 population is enriched for tumors with a poor prognosis but is still heterogeneous in terms of rates of pCR and RFS. The ability of pCR to predict RFS is better by subset than it is for the whole group. Molecular markers improve prediction of RFS by identifying additional patients with excellent prognosis within the no pCR group.

Original languageEnglish (US)
Pages (from-to)1049-1062
Number of pages14
JournalBreast Cancer Research and Treatment
Volume132
Issue number3
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Biomarkers
Breast Neoplasms
Recurrence
Drug Therapy
Survival
Neoplasms
Molecular Imaging
Wound Healing
Population
Multivariate Analysis
Hormones
Mutation
Genes

Keywords

  • Breast cancer
  • Molecular biomarkers
  • Neoadjuvant chemotherapy
  • Pathologic complete response

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chemotherapy response and recurrence-free survival in Neoadjuvant breast cancer depends on biomarker profiles : Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). / Esserman, Laura J.; Berry, Donald A.; Cheang, Maggie C U; Yau, Christina; Perou, Charles M.; Carey, Lisa; De Michele, Angela; Gray, Joe W.; Conway-Dorsey, Kathleen; Lenburg, Marc E.; Buxton, Meredith B.; Davis, Sarah E.; Van't Veer, Laura J.; Hudis, Clifford; Chin, Koei; Wolf, Denise; Krontiras, Helen; Montgomery, Leslie; Tripathy, Debu; Lehman, Constance; Liu, Minetta C; Olopade, Olufunmilayo I.; Rugo, Hope S.; Carpenter, John T.; Livasy, Chad; Dressler, Lynn; Chhieng, David; Singh, Baljit; Mies, Carolyn; Rabban, Joseph; Chen, Yunni Yi; Giri, Dilip; Au, Alfred; Hylton, Nola.

In: Breast Cancer Research and Treatment, Vol. 132, No. 3, 04.2012, p. 1049-1062.

Research output: Contribution to journalArticle

Esserman, LJ, Berry, DA, Cheang, MCU, Yau, C, Perou, CM, Carey, L, De Michele, A, Gray, JW, Conway-Dorsey, K, Lenburg, ME, Buxton, MB, Davis, SE, Van't Veer, LJ, Hudis, C, Chin, K, Wolf, D, Krontiras, H, Montgomery, L, Tripathy, D, Lehman, C, Liu, MC, Olopade, OI, Rugo, HS, Carpenter, JT, Livasy, C, Dressler, L, Chhieng, D, Singh, B, Mies, C, Rabban, J, Chen, YY, Giri, D, Au, A & Hylton, N 2012, 'Chemotherapy response and recurrence-free survival in Neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)', Breast Cancer Research and Treatment, vol. 132, no. 3, pp. 1049-1062. https://doi.org/10.1007/s10549-011-1895-2
Esserman, Laura J. ; Berry, Donald A. ; Cheang, Maggie C U ; Yau, Christina ; Perou, Charles M. ; Carey, Lisa ; De Michele, Angela ; Gray, Joe W. ; Conway-Dorsey, Kathleen ; Lenburg, Marc E. ; Buxton, Meredith B. ; Davis, Sarah E. ; Van't Veer, Laura J. ; Hudis, Clifford ; Chin, Koei ; Wolf, Denise ; Krontiras, Helen ; Montgomery, Leslie ; Tripathy, Debu ; Lehman, Constance ; Liu, Minetta C ; Olopade, Olufunmilayo I. ; Rugo, Hope S. ; Carpenter, John T. ; Livasy, Chad ; Dressler, Lynn ; Chhieng, David ; Singh, Baljit ; Mies, Carolyn ; Rabban, Joseph ; Chen, Yunni Yi ; Giri, Dilip ; Au, Alfred ; Hylton, Nola. / Chemotherapy response and recurrence-free survival in Neoadjuvant breast cancer depends on biomarker profiles : Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). In: Breast Cancer Research and Treatment. 2012 ; Vol. 132, No. 3. pp. 1049-1062.
@article{e056dfdc19be49989b39c73b760040eb,
title = "Chemotherapy response and recurrence-free survival in Neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)",
abstract = "Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging and molecular signatures, with outcomes of pathologic complete response (pCR) and RFS. The current analysis was performed using data from patients who had molecular profiles and did not receive trastuzumab. The various molecular classifiers tested were highly correlated. Categorization of breast cancer by molecular signatures enhanced the ability of pCR to predict improvement in RFS compared to the population as a whole. In multivariate analysis, the molecular signatures that added to the ability of HR and HER2 receptors, clinical stage, and pCR in predicting RFS included 70-gene signature, wound healing signature, p53 mutation signature, and PAM50 risk of recurrence. The low risk signatures were associated with significantly better prognosis, and also identified additional patients with a good prognosis within the no pCR group, primarily in the hormone receptor positive, HER-2 negative subgroup. The I-SPY 1 population is enriched for tumors with a poor prognosis but is still heterogeneous in terms of rates of pCR and RFS. The ability of pCR to predict RFS is better by subset than it is for the whole group. Molecular markers improve prediction of RFS by identifying additional patients with excellent prognosis within the no pCR group.",
keywords = "Breast cancer, Molecular biomarkers, Neoadjuvant chemotherapy, Pathologic complete response",
author = "Esserman, {Laura J.} and Berry, {Donald A.} and Cheang, {Maggie C U} and Christina Yau and Perou, {Charles M.} and Lisa Carey and {De Michele}, Angela and Gray, {Joe W.} and Kathleen Conway-Dorsey and Lenburg, {Marc E.} and Buxton, {Meredith B.} and Davis, {Sarah E.} and {Van't Veer}, {Laura J.} and Clifford Hudis and Koei Chin and Denise Wolf and Helen Krontiras and Leslie Montgomery and Debu Tripathy and Constance Lehman and Liu, {Minetta C} and Olopade, {Olufunmilayo I.} and Rugo, {Hope S.} and Carpenter, {John T.} and Chad Livasy and Lynn Dressler and David Chhieng and Baljit Singh and Carolyn Mies and Joseph Rabban and Chen, {Yunni Yi} and Dilip Giri and Alfred Au and Nola Hylton",
year = "2012",
month = "4",
doi = "10.1007/s10549-011-1895-2",
language = "English (US)",
volume = "132",
pages = "1049--1062",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Chemotherapy response and recurrence-free survival in Neoadjuvant breast cancer depends on biomarker profiles

T2 - Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

AU - Esserman, Laura J.

AU - Berry, Donald A.

AU - Cheang, Maggie C U

AU - Yau, Christina

AU - Perou, Charles M.

AU - Carey, Lisa

AU - De Michele, Angela

AU - Gray, Joe W.

AU - Conway-Dorsey, Kathleen

AU - Lenburg, Marc E.

AU - Buxton, Meredith B.

AU - Davis, Sarah E.

AU - Van't Veer, Laura J.

AU - Hudis, Clifford

AU - Chin, Koei

AU - Wolf, Denise

AU - Krontiras, Helen

AU - Montgomery, Leslie

AU - Tripathy, Debu

AU - Lehman, Constance

AU - Liu, Minetta C

AU - Olopade, Olufunmilayo I.

AU - Rugo, Hope S.

AU - Carpenter, John T.

AU - Livasy, Chad

AU - Dressler, Lynn

AU - Chhieng, David

AU - Singh, Baljit

AU - Mies, Carolyn

AU - Rabban, Joseph

AU - Chen, Yunni Yi

AU - Giri, Dilip

AU - Au, Alfred

AU - Hylton, Nola

PY - 2012/4

Y1 - 2012/4

N2 - Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging and molecular signatures, with outcomes of pathologic complete response (pCR) and RFS. The current analysis was performed using data from patients who had molecular profiles and did not receive trastuzumab. The various molecular classifiers tested were highly correlated. Categorization of breast cancer by molecular signatures enhanced the ability of pCR to predict improvement in RFS compared to the population as a whole. In multivariate analysis, the molecular signatures that added to the ability of HR and HER2 receptors, clinical stage, and pCR in predicting RFS included 70-gene signature, wound healing signature, p53 mutation signature, and PAM50 risk of recurrence. The low risk signatures were associated with significantly better prognosis, and also identified additional patients with a good prognosis within the no pCR group, primarily in the hormone receptor positive, HER-2 negative subgroup. The I-SPY 1 population is enriched for tumors with a poor prognosis but is still heterogeneous in terms of rates of pCR and RFS. The ability of pCR to predict RFS is better by subset than it is for the whole group. Molecular markers improve prediction of RFS by identifying additional patients with excellent prognosis within the no pCR group.

AB - Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging and molecular signatures, with outcomes of pathologic complete response (pCR) and RFS. The current analysis was performed using data from patients who had molecular profiles and did not receive trastuzumab. The various molecular classifiers tested were highly correlated. Categorization of breast cancer by molecular signatures enhanced the ability of pCR to predict improvement in RFS compared to the population as a whole. In multivariate analysis, the molecular signatures that added to the ability of HR and HER2 receptors, clinical stage, and pCR in predicting RFS included 70-gene signature, wound healing signature, p53 mutation signature, and PAM50 risk of recurrence. The low risk signatures were associated with significantly better prognosis, and also identified additional patients with a good prognosis within the no pCR group, primarily in the hormone receptor positive, HER-2 negative subgroup. The I-SPY 1 population is enriched for tumors with a poor prognosis but is still heterogeneous in terms of rates of pCR and RFS. The ability of pCR to predict RFS is better by subset than it is for the whole group. Molecular markers improve prediction of RFS by identifying additional patients with excellent prognosis within the no pCR group.

KW - Breast cancer

KW - Molecular biomarkers

KW - Neoadjuvant chemotherapy

KW - Pathologic complete response

UR - http://www.scopus.com/inward/record.url?scp=84865191389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865191389&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1895-2

DO - 10.1007/s10549-011-1895-2

M3 - Article

C2 - 22198468

AN - SCOPUS:84865191389

VL - 132

SP - 1049

EP - 1062

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -